Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABBR2 | O75899 | 2/20 | 0.36 |
| ▸ | GABBR1 | Q9UBS5 | 2/20 | 0.36 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | ANPEP | P15144 | 4/20 | 0.32 |
| ▸ | LAP3 | P28838 | 4/20 | 0.32 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20841435 | 0.80 | ANPEP (0.39) | GABBR2GABBR1GABRR1ANPEPLAP3 | |
| SCHEMBL16333883 | 0.78 | ANPEP (0.37) | GABBR2GABBR1GABRR1ANPEPLAP3 | |
| SCHEMBL1357583 | 0.77 | TSHR (0.41) | GABBR2GABBR1GABRR1TSHRLAP3 | |
| SCHEMBL28865310 | 0.77 | GABBR2 (0.39) | GABBR2GABBR1GABRR1TSHRTDP1 | |
| SCHEMBL1533820 | 0.77 | — | — | |
| SCHEMBL27963724 | 0.77 | — | — | |
| SCHEMBL8762129 | 0.74 | — | — | |
| SCHEMBL2171194 | 0.74 | TSHR (0.35) | TSHRTDP1ANPEPLAP3ERAP1 | |
| SCHEMBL11871518 | 0.73 | TSHR (0.39) | GABBR2GABBR1GABRR1TSHRTDP1 | |
| SCHEMBL2486684 | 0.73 | ALDH1A1 (0.39) | TDP1ANPEPLAP3ERAP1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9068119-B2 | Method for producing mono-hydroxy-functionalized dialkylphosphinic acids, esters and salts using a vinyl ester of a carobxylic acid and the use thereof | CLARIANT FINANCE (BVI) LIMITED (VG) | 2015-06-30 | — | — | US | disclosed |
| US-8987490-B2 | Method for the production of monohydroxy-functionalized dialkylphosphinic acids, esters, and salts using ethylene oxide, and use thereof | CLARIANT FINANCE (BVI) LIMITED (VG) | 2015-03-24 | — | — | US | disclosed |
| EP-2373668-B1 | METHOD FOR PRODUCING MONO-HYDROXY-FUNCTIONALIZED DIALKYLPHOSPHINIC ACIDS, ESTERS AND SALTS USING A VINYL ESTER OF A CARBOXYLIC ACID AND THE USE THEREOF | CLARIANT FINANCE BVI LTD (VG) | 2013-09-11 | — | — | EP | disclosed |
| US-20110281983-A1 | Method for the Production of Monohydroxy-Functionalized Dialkylphosphinic Acids, Esters, and Salts Using Ethylene Oxide, and Use Thereof | CLARIANT FINANCE (BVI) LIMITED (VG) | 2011-11-17 | — | — | US | disclosed |
| EP-2379574-A1 | METHOD FOR THE PRODUCTION OF MONOHYDROXY-FUNCTIONALIZED DIALKYLPHOSPHINIC ACIDS, ESTERS, AND SALTS USING ETHYLENE OXIDE, AND USE THEREOF | Clariant International Ltd. (CH) | 2011-10-26 | — | — | EP | disclosed |
| EP-2373668-A1 | METHOD FOR PRODUCING MONO-HYDROXY-FUNCTIONALIZED DIALKYLPHOSPHINIC ACIDS, ESTERS AND SALTS USING A VINYL ESTER OF A CARBOXYLIC ACID AND THE USE THEREOF | Clariant International Ltd. (CH) | 2011-10-12 | — | — | EP | disclosed |
| US-20110237722-A1 | Method for Producing Mono-Hydroxy-Functionalized Dialkylphosphinic Acids, Esters and Salts Using a Vinyl Ester of a Carobxylic Acid and The Use Thereof | CLARIANT FINANCE (BVI) LIMITED (VG) | 2011-09-29 | — | — | US | disclosed |
| WO-2010069417-A1 | METHOD FOR THE PRODUCTION OF MONOHYDROXY-FUNCTIONALIZED DIALKYLPHOSPHINIC ACIDS, ESTERS, AND SALTS USING ETHYLENE OXIDE, AND USE THEREOF | CLARIANT INTERNATIONAL LTD (CH) | 2010-06-24 | — | — | WO | disclosed |
| WO-2010063343-A1 | METHOD FOR PRODUCING MONO-HYDROXY-FUNCTIONALIZED DIALKYLPHOSPHINIC ACIDS, ESTERS AND SALTS USING A VINYL ESTER OF A CARBOXYLIC ACID AND THE USE THEREOF | CLARIANT INTERNATIONAL LTD (CH) | 2010-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237722-A1 | Method for Producing Mono-Hydroxy-Functionalized Dialkylphosphinic Acids, Esters and Salts Using a Vinyl Ester of a Carobxylic Acid and The Use Thereof | HAO2, HACL2, HAO1 | GABBR2 1026/4885GABBR1 1205/4885GABRR1 3154/4885 |
| US-20110281983-A1 | Method for the Production of Monohydroxy-Functionalized Dialkylphosphinic Acids, Esters, and Salts Using Ethylene Oxide, and Use Thereof | ACSL3, ACSL1, HACL2 | GABBR2 3074/4885GABBR1 3677/4885GABRR1 3632/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.